Takeda launches cdpath™, a personalized prognostic tool, advancing innovation for patients with crohn's disease

Cdpath supports shared decision-making between patients and healthcare providers; provided at no cost to eligible adult patients who have not yet experienced serious complications* cambridge, mass. , sept. 14, 2022 /prnewswire/ -- takeda ( tse:4502/nyse:tak ) today announced the national launch of the cdpath™ program, which includes an innovative, validated personalized prognostic tool that uses blood tests† to help predict the potential risk of developing serious crohn's disease-related complications within three years.1,2 cdpath is available for use by us-based physicians and offered at no cost to eligible patients††, providing an opportunity for patients to partner with their physicians to map out a personalized disease management plan.
DGX Ratings Summary
DGX Quant Ranking